Journal of Clinical Oncology
Articles in this Issue
Cross-modality AI modeling of histopathology images to stratify outcomes among patients treated with hormonal or chemo-hormonal therapy in ER+/HER2− breast cancer.
1028 Background: Oncotype DX (ODX) is widely used to guide adjuvant treatment decisions in early-stage ER+/HER2− breast ca...
Integrating BTK inhibition into R-da-EPOCH for HIV-related DLBCL.
7001 Background: Human immunodeficiency virus (HIV)-related diffuse large B-cell lymphomas (DLBCL) are heterogeneous in na...
Prevalence and trends in rural patient enrollment in SWOG cancer clinical trials, 1992-2022.
11068 Background: A recent ASCO report highlighted improving patient access to cancer clinical trials as a fundamental pri...
A retrospective analysis of tarlatamab outcomes and safety in a global multicenter electronic health record network (TriNetX) database.
e20167 Background: Tarlatamab, a bispecific T-cell engager (BiTE) targeting Delta-like Ligand 3 (DLL3), has been approved...
CONCEPT (combination of cetuximab plus fruquintinib treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR <i>RAS/BRAF</i> wild-type unresectable metastatic colorectal cancer.
TPS3680 Background: In pMMR unresectable metastatic colorectal cancer (mCRC), first-line standards combine cytotoxic chemo...
Real-world adoption and sequencing of CLDN18.2, PD-L1, and HER2 testing in advanced gastric and gastroesophageal junction adenocarcinoma.
4035 Background: The FDA approval of zolbetuximab for CLDN18.2-positive advanced gastric and gastroesophageal junction ade...
Neoadjuvant immunotherapy combined with immunonutrition therapy for gastric cancer: A single-center, randomized clinical trial.
e16054 Background: This study aimed to explore whether immunonutrition therapy could enhance the efficacy of gastric cance...
Early therapeutic intervention versus observation in high-risk smoldering multiple myeloma: A systematic review and meta-analysis.
e19547 Background: Smoldering multiple myeloma (SMM) is an asymptomatic precursor to multiple myeloma (MM) with heterogene...
Cladribine (CLAD) + low-dose AraC (LDAC) + venetoclax (VEN) in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome: Real-world analysis from a large community-based oncology practice.
6542 Background: A lower intensity combination cladribine (CLAD), low dose cytarabine (LDAC), and venetoclax (VEN), altern...
Factors influencing the decision for contralateral risk-reducing mastectomy in Japanese patients with breast cancer harboring <i>BRCA1/2</i> pathogenic variants: The BRCA-Decision study.
e22661 Background: Contralateral risk-reducing mastectomy (CRRM) is an option for reducing contralateral breast cancer ris...
Disparities in incidence and stage at presentation of hepatocellular carcinoma: A SEER-based study of disaggregated AANHPI populations.
e13734 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in the United States. The...
CHRONO: A randomized phase II trial of the chronology of surgery after neoadjuvant chemotherapy for ovarian cancer.
5505 Background: In patients treated for advanced ovarian cancer not suitable for complete primary surgery, interval surge...
Treatment sequencing after adjuvant treatment failure in patients with melanoma: A retrospective cohort study.
e21540 Background: Despite risk reduction for recurrence with adjuvant immune checkpoint inhibitors (ICI) and targeted the...
Comprehensive oncology research mapping in Morocco: Patterns, quality, and unmet needs.
e23185 Background: The Moroccan oncology research landscape is constrained by limited infrastructure, uneven capacity and...
Immune-related thyroid dysfunction and overall survival in metastatic colorectal cancer treated with pembrolizumab: A real-world TriNetX analysis.
e15558 Background: Immune checkpoint inhibitors (ICIs) are standard therapy for MSI-H/dMMR metastatic colorectal cancer (C...
Racial disparities and sex differences in the incidence of HPV-positive cancers: A SEER database study.
e22619 Background: Human papilloma virus (HPV) is a viral infection that can cause malignant changes in infected tissues a...
Genomic landscape and patient demographics in endocervical adenocarcinoma: Insights from the AACR Project GENIE.
5531 Background: Endocervical Adenocarcinoma (EA) makes up 20-25% of cases of cervical cancer, and has an 80-90% associati...
Fixed-duration subcutaneous (SC) mosunetuzumab (Mosun) in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Interim analysis and patient-reported outcomes (PROs) from the phase 2 MorningSun study.
7029 Background: Mosun, a CD20xCD3 T-cell engaging bispecific antibody, is approved for relapsed/refractory follicular lym...
FIRE-4 (AIO KRK-0114): Efficacy of third-line rechallenge with cetuximab versus investigator’s choice in relation to the interval between initial and third-line anti-EGFR therapy.
3575 Background: The randomized FIRE-4 study evaluated the effect of cetuximab rechallenge versus investigator’s choice in...
A multicenter, open-label, single-arm, dose-finding and -expansion phase 1b/2 study to evaluate the safety and tolerability of nesuparib (JPI-547) in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer.
TPS4247 Background: Recurrent or metastatic gastric cancer (GC) progressing after standard first- and second-line therapie...
Spatial immune profiling to identify GPNMB as a mediator of immune suppression that limits response to PD-1 blockade in TNBC.
2582 Background: Breast cancer (BC) is the leading cause of female cancer-related deaths. Triple-negative BC (TNBC), accou...
Epidemiology of typical and atypical lung neuroendocrine tumors in a rural U.S. population.
e22631 Background: Lung neuroendocrine neoplasms comprise a heterogeneous group of tumors that include typical and atypica...
Late line treatment in hormone receptor positive, her 2 neu positive metastatic breast cancer with fulvestrant, abemaciclib, and trastuzumab, including prolonged CNS control.
e14010 Background: Since trastuzumab was introduced in 1998, her 2 targeted treatment has become the standard of care. We...
Standardized birth rates and access to assisted reproductive technology among female cancer patients in the United States.
12105 Background: Fertility after cancer is critically under-defined on a national scale, reflecting a substantial gap in...
Comparison of chemotherapy–immunotherapy and chemoradiation in esophageal cancer: A TriNetX real-world evidence study.
e16116 Background: Although chemoimmunotherapy is widely used in esophageal cancer, real-world comparisons with standard c...